A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis (NEPTUNE)

  • End date
    Jul 11, 2024
  • participants needed
  • sponsor
    Priovant Therapeutics, Inc.
Updated on 11 October 2022


This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Condition Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
Treatment Brepocitinib
Clinical Study IdentifierNCT05523765
SponsorPriovant Therapeutics, Inc.
Last Modified on11 October 2022


Yes No Not Sure

Inclusion Criteria

Adult subjects (18-74 years old)
Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator
Active, inflammatory chorioretinal and/or retinal vascular lesion; OR
≥2+ vitreous haze grade (NEI/SUN criteria)
Receiving ongoing (or initiated during screening) therapy with oral prednisone
Receiving up to one non-corticosteroid, non-biologic, immunomodulatory therapy
Weight > 40 kg with a body mass index < 40 kg/m2

Exclusion Criteria

Has isolated anterior uveitis
Has confirmed or suspected current diagnosis of infectious uveitis
History of
Any lymphoproliferative disorder
Active malignancy
History of cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
At a risk of thrombosis and cardiovascular disease
Have a high risk for herpes zoster reactivation
Have active or recent infections
Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note